| Literature DB >> 36193044 |
Mirjam Münch1,2,3, Rolf Goldbach4, Naomi Zumstein5,6, Petra Vonmoos7, Jean-Louis Scartezzini1, Anna Wirz-Justice2, Christian Cajochen2,3.
Abstract
Enhancing lighting conditions in institutions for individuals with dementia improves their sleep, circadian rhythms and well-being. Here, we report first findings that exposure to brighter light during daytime may support the immune response to the annual influenza vaccination. Eighty older institutionalised patients suffering from dementia (54 women and 26 men) continuously wore an activity tracker for 8 weeks to assess individual light exposure and rest-activity cycles. We analysed the patients' immune response from two blood samples taken before and 4 weeks after the annual influenza vaccination. Individual antibody concentrations to three influenza virus strains (H3N2, H1N1, IB) were quantified via hemagglutination inhibition assays. By quantifying individual light exposure profiles (including daylight), we classified the patients into a low and a high light exposure group based on a median illuminance of 392.6 lux. The two light exposure groups did not differ in cognitive impairment severity, age or gender distribution. However, patients in the high light exposure group showed a significantly greater circadian rest-activity amplitude (i.e., more daytime activity and less nighttime activity) along with a significantly greater antibody titer increase to the H3N2 vaccine than patients in the low light exposure group, despite similar pre-vaccination concentrations. Sufficient seroprotective responses to all three influenza virus strains were attained for ≥75% of participants. These data provide preliminary evidence for a potentially enhanced immune response in patients with dementia when they received more daily light. Future studies are needed to determine whether regular daily light exposure may have beneficial effects on the human immune system, either directly or via a stabilising circadian sleep-wake rhythms.Entities:
Keywords: Circadian; Flu shot; IS, Inter-daily Stability; IV, Intradaily Variability; Immunology; Light; Neurodegeneration; Rest-activity; SCN, Suprachiasmatic Nucleus; Sleep
Year: 2022 PMID: 36193044 PMCID: PMC9526132 DOI: 10.1016/j.bbih.2022.100515
Source DB: PubMed Journal: Brain Behav Immun Health ISSN: 2666-3546
Demographics and comorbidities (derived from medical charts): AD = Alzheimer Dementia; MT = Mixed Dementia; P=Parkinson Dementia; U=Unspecified dementia type; V=Vascular; S-MMSE = Severe-Mini-Mental Status Examination. Comorbidities are listed according to the medical diagnosis (medical chart). TIA = transitory ischemic attack; PRIND = prolonged reversible ischemic neurological Deficit;a = difference between both light groups is not statistically significant (p > 0.05).
| Demographics: | Low Light Group (n = 40; | High light group (n = 40) |
|---|---|---|
| Age (mean ± SD)a | 79.0 ± 9.2 | 77.7 ± 9.2 |
| Sex | 27 w/13 m | 27 w/13 m |
| Type of Dementia | AD 21; FT 1 MT 11; P 1; U: 6; V 0 | AD 16; FT 2; MT 9; P 1; U 11; V 1 |
| S-MMSE (mean ± SD)a | 8.1 ± 9.8 | 7.8 ± 9.6 |
| Cancer | 5 | 5 |
| Cardio-vascular (Hypertension, Congenital heart failure, coronary artery disease) | 24 | 17 |
| Chronic respiratory disease (asthma, chronic obstructive pulmonary disease, sleep apnea) | 3 | 2 |
| Kidney disease | 6 | 5 |
| Liver/Pancreas disease | 1 | |
| Metabolic disease (Diabetes mellitus, obesity) | 3 | 5 |
| Gastrointestinal (reflux oesophagitis, stomach ulcera, colitis) | 7 | 3 |
| Epilepsy | 4 | 9 |
| Brain Insult (TIA, PRIND, ischemic attacks) | 3 | 3 |
| Depression | 21 | 20 |
Circadian and sleep variables (derived from activity monitors) for low and high light exposure (low LE, high LE) groups (mean, SD in brackets; n = 80). IS = Inter-daily stability; IV = intra-daily variability; L5 = 5 h with lowest activity; M10 = 10 h with highest activity; RA = relative amplitude (see Ref (Van Someren et al., 1999) for more details); BT = habitual bedtime (h); WT = habitual waketime (h); TIB = Time in bed (h); Wake = waketime during scheduled sleep (h); Sleep duration (h); SE = sleep efficiency (%; sleep time/TIB x 100); Fragmentation Index (dimensionless). * = p < 0.05 between light exposure groups (bold).
| Variable | Low Light Exposure Group | SD | High Light Exposure Group | SD |
|---|---|---|---|---|
| IV | 1.05 | (0.30) | 1.18 | (0.38) |
| L5 | 705.77 | (591.84) | 655.15 | (625.49) |
| M10 | 3969.53 | (3263.18) | 4241.26 | (3756.49) |
| BT (h) | 19.50 | (1.00) | 19.57 | (1.31) |
| WT (h) | 8.24 | (0.71) | 8.10 | (0.79) |
| TIB (h) | 12.71 | (1.25) | 12.52 | (1.73) |
| Wake (h) | 2.14 | (1.26) | 1.84 | (1.09) |
| Sleep duration (h) | 10.28 | (2.26) | 10.40 | (2.48) |
| SE (%) | 80.09 | (12.08) | 82.23 | (10.90) |
| Fragmentation Index | 50.81 | (24.87) | 46.69 | (18.86) |
Blood analyses before and 6 weeks after the influenza vaccination. CRP = C-reactive protein, LC = leucocytes, EC = erythrocytes, HB = haemoglobin, HK = haematocrit, MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration, TC = thrombocytes, LUC = large unstained cells, FACS = fluorescence activated cell sorting (CD3, CD4, CD8); means and (SEM); n = 80; *= p < 0.05; main difference between pre- and post-vaccine session (bold).
| Blood Marker | Pre-vaccination (SEM) | Post-vaccination (SEM) | ||
|---|---|---|---|---|
| CD4 (count/μl) | 879.23 | (33.17) | 892.61 | (36.09) |
| CD8 (count/μl) | 435.74 | (35.63) | 448.29 | (33.43) |
| CD4/CD8 Ratio | 2.76 | (0.19) | 2.65 | (0.18) |
| CRP (mg/l) | 10.40 | (2.03) | 6.59 | (1.03) |
| EC (G/l) | 4.37 | (0.06) | 4.32 | (0.05) |
| HB (g/l) | 130.09 | (1.70) | 128.85 | (1.57) |
| HK (l/l) | 0.40 | (0.005) | 0.39 | (0.004) |
| MCV (fl) | 90.64 | (0.52) | 90.94 | (0.48) |
| MCH (pg) | 29.77 | (0.19) | 29.85 | (0.16) |
| MCHC (g/l) | 328.40 | (0.87) | 328.43 | (0.78) |
| TC (G/l) | 292.91 | (8.60) | 284.41 | (8.24) |
| Eosinophil (%) | 3.66 | (0.26) | 4.12 | (0.41) |
| Basophil (%) | 0.53 | (0.03) | 0.54 | (0.03) |
| Monocytes (%) | 6.07 | (0.19) | 6.17 | (0.15) |
| FACS (count/μl) | 1331.20 | (57.60) | 1358.33 | (55.55) |
Absolute influenza antibody titers pre- and post-vaccination for three virus strains: H3N2 (n = 78), H1N1 (n = 79) and IB (n = 80) as well as ratio (post/pre) for the low and high light group; means and (SEM). * = significant differences between ratio of the low and the high light exposure group (p < 0.05; main effect of light exposure group, in bold).
| Titer | Low Light Exposure Group | High Light Exposure Group | ||
|---|---|---|---|---|
| Pre (H3N2) | 140.8 | (12.3) | 150.3 | (25.3) |
| Post (H3N2) | 421.3 | (69.2) | 627.5 | (146.3) |
| Pre (H1N1) | 39.5 | (8.4) | 62.5 | (12.3) |
| Post (H1N1) | 477.5 | (93.8) | 401.6 | (112.6) |
| Ratio (H1N1) | 31.1 | (7.9) | 26.7 | (9.4) |
| Pre (IB) | 65.4 | (9.4) | 56.0 | (9.4) |
| Post (IB) | 232.6 | (61.2) | 201.9 | (29.5) |
| Ratio (IB) | 5.6 | (1.6) | 9.7 | (2.4) |
Fig. 1Mean values (+SEM) for antibody titer ratios (post-vaccination/pre-vaccination) for all three influenza strains and both sub-groups of patients [high (red bars) vs. low light exposure group (black bars)]: H3N2 (n = 78); H1N1 (n = 79); IB (n = 80). *: p = 0.01 (main effect of light exposure group) and trend: #: p = 0.08. . (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2Reverse curve distribution plots from geometric mean antibody titers (GMT) for pre-vaccination and post-vaccination samples and the three influenza virus strains (H3N2, upper graph; H1N1, middle graph; IB, lower graph). The data is expressed in percentage for both light exposure groups of patients separately; left panel = low light exposure group; right panel = high light exposure group (filled grey and orange triangles down and grey lines and orange lines = pre-vaccination antibody titers; open black and red triangles up and black and red lines = post-vaccination titers). The vertical line in each graph represents the threshold for GMT titers of seroprotection by the influenza vaccination (i.e., a GMT ≥40). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3Simplified schema illustrating lower environmental light exposures (left panel) via retino-hypothalamic neuronal projections to the SCN in the brain elicit lower circadian amplitude of rest-activity cycles and probably other circadian rhythms and a consequently lower specific antibody production as it is for example known in night shift workers (Ruiz et al., 2020). The same potential pathway of action is shown on the right panel but for higher light exposures, which results in higher antibody responses. The question marks illustrate the hypothesised open research questions.